Cortistatin-14
Based on 1 publication(s) in Google Scholar
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.98%
- CAS. Nr.: 186901-48-4
- Formel: C81H114N20O18S2
- Molecular Weight:1720.03
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cortistatin-14
More
Biologische Aktivität
|
SSTR1 |
SSTR2 |
SSTR3 |
SSTR4 |
SSTR5 |
Cortistatin-14 (100-10000 nM, 8-24 min) reduces the release of calcitonin gene-related peptide from peripheral sensory nerve endings in the isolated trachea of rats induced by capsaicin (HY-10448) [1].
CST-14 (0.1-10 μg/mL, 8 h) significantly decreases the secretion of the cytokine IL-1β in mouse peritoneal macrophages [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cortistatin-14 (10 μg; intravenous injection; single dose) plays a regulatory role in the pituitary secretion of male rats[2].
Cortistatin-14 (1-10 nM, intracerebroventricular injection; single dose) has anticonvulsant and neuroprotective effects in rats by binding to somatostatin receptors, which leads to a reduction in the release of excitatory neurotransmitters[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hydrochloride-induced rat[3]
-
Dosage:1 and 10 nM; single dose
-
Administration:Intracerebroventricular injection (ICV)
-
Result:Relieved epilepsy, inhibited neuronal loss, prevented the reduction of immune-active somatostatin and its receptors in the hippocampus, and reduced the release of 3H-D-aspartate under stimulation.
-
Animal Model:Endotoxin-stimulated mice[1]
-
Dosage:10 μg/kg (i.p.); 100 μg/kg (i.p.); 250 μg/kg (i.pl.); six times a day
-
Administration:Intraperitoneal injection (i.p.); i.pl.
-
Result:Reduced the concentrations of TNF-α and IL-1β, reduced mustard oil-induced plasma protein extravasation in the dorsal skin, with an inhibition rate of nearly 80%, inhibited plantar thermal hyperalgesia in rats caused by mild thermal injury (51°C, 20 seconds).
-
Animal Model:Wistar-Kyoto rat[2]
-
Dosage:10 μg; single dose
-
Administration:Intravenous injection (i.v.)
-
Result:Reduced growth hormone concentrations without affecting LH and FSH concentrations.
Chemical Information
-
CAS. Nr. 186901-48-4
-
Appearance Solid
-
Molecular Weight 1720.03
-
Formel C81H114N20O18S2
-
Color White to off-white
-
Sequence
{Pro}{Cys}{Lys}{Asn}{Phe}{Phe}{Trp}{Lys}{Thr}{Phe}{Ser}{Ser}{Cys}{Lys}-NH2 (Disulfide bridge: Cys2-Cys13)
-
Sequence Shortening
PCKNFFWKTFSSCK-NH2 (Disulfide bridge: Cys2-Cys13)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Genistein alleviates skin inflammation in atopic dermatitis by inhibiting mast cell degranulation through toll-like receptor. [Abstract]2026 May 15:157:158308. PMID: 42184496
Lösungsmittel & Löslichkeit
H2O : 100 mg/mL (58.14 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (58.14 mM); Clear solution; Need ultrasonic
Reinheit & Dokumentation
-
Data Sheet (290 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Markovics A, et al. Comparison of the anti-inflammatory and anti-nociceptive effects of cortistatin-14 and somatostatin-14 in distinct in vitro and in vivo model systems. J Mol Neurosci. 2012 Jan;46(1):40-50. [Content Brief]
[2]. Baranowska B, et al. Cortistatin and pituitary hormone secretion in rat. J Physiol Pharmacol. 2009 Mar;60(1):151-6. [Content Brief]
[3]. Braun H, et al. Protective effects of cortistatin (CST-14) against kainate-induced neurotoxicity in rat brain. Brain Res. 1998 Aug 24;803(1-2):54-60. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.5814 mL | 2.9069 mL | 5.8139 mL | 14.5346 mL |
| 5 mM | 0.1163 mL | 0.5814 mL | 1.1628 mL | 2.9069 mL | |
| 10 mM | 0.0581 mL | 0.2907 mL | 0.5814 mL | 1.4535 mL | |
| 15 mM | 0.0388 mL | 0.1938 mL | 0.3876 mL | 0.9690 mL | |
| 20 mM | 0.0291 mL | 0.1453 mL | 0.2907 mL | 0.7267 mL | |
| 25 mM | 0.0233 mL | 0.1163 mL | 0.2326 mL | 0.5814 mL | |
| 30 mM | 0.0194 mL | 0.0969 mL | 0.1938 mL | 0.4845 mL | |
| 40 mM | 0.0145 mL | 0.0727 mL | 0.1453 mL | 0.3634 mL | |
| 50 mM | 0.0116 mL | 0.0581 mL | 0.1163 mL | 0.2907 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cortistatin-14 Related Classifications
HY-P1932 Related Classifications
Powered by Bioz